Related Experiment Video

Updated: Jan 4, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K

The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target

Anindya Goswami1, Padhma Ranganathan, Vivek M Rangnekar

  • 1Department of Radiation Medicine, University of Kentucky, Lexington, KY 40536, USA.

Cancer Research
|March 17, 2006
PubMed

Insights

The phosphoinositide 3-kinase (PI3K)/Akt pathway promotes cancer cell survival. Targeting the proapoptotic protein Par-4, inactivated by this pathway, offers a strategy for cancer-selective therapeutics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The phosphoinositide 3-kinase (PI3K)/Akt pathway is frequently activated in cancers, promoting cell survival.
  • This pathway's role in normal cell survival necessitates cancer-selective therapeutic strategies.
  • The tumor suppressor PTEN normally inhibits PI3K/Akt signaling.

Purpose of the Study:

  • To investigate the role of the proapoptotic protein Par-4 in cancer cell survival.
  • To explore the relationship between PI3K/Akt signaling and Par-4.
  • To assess the potential of Par-4 as a target for cancer-selective therapies.

Main Methods:

  • Investigated the inactivation of Par-4 by PI3K/Akt signaling.
  • Examined the interplay between PTEN, PI3K/Akt, and Par-4.
  • Evaluated Par-4's function in apoptosis mediation.

Main Results:

  • PI3K/Akt signaling inactivates the cancer-selective proapoptotic protein Par-4.
  • Par-4 is involved in mediating apoptosis induced by PTEN.
  • Par-4 plays a central role in cancer cell survival.

Conclusions:

  • Par-4 is a key target for PI3K/Akt inactivation in cancer.
  • Targeting Par-4 may lead to the development of novel cancer-selective therapeutics.
  • Modulating Par-4 offers a promising approach for cancer treatment.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.5K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.0K